DÄ internationalArchive42/2006A Generalist Perspective on Second-Generation Antipsychotics

Review article

A Generalist Perspective on Second-Generation Antipsychotics

Dtsch Arztebl 2006; 103(42): A-2802

Agelink, M W; Kornischka, J; Cordes, J; Klimke, A; Hauner, H; Ziegler, D

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Windgassen K, Bick O: Fortschritte in der neuroleptischen Schizophreniebehandlung. Dtsch Arztebl 2004; 101(48): A3270–5. VOLLTEXT
2. Holt RJ, Peveler RC, Byrne CD: Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21: 515–23. MEDLINE
3. McEvoy JP, Meyer JM, Goff DC et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effictiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32. MEDLINE
4. Himmerich H, Schuld A, Pollmächer T: Gewichtszunahme unter Psychopharmakotherapie. Dtsch Arztebl 2005; 102(31–32): A 2172–7. VOLLTEXT
5. Allison DB, Mentore JL, Heo M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96. MEDLINE
6. Lieberman JA, Stroup TS, McEvoy PJ et al.: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl Med J 2005; 353: 1209–23. MEDLINE
7. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601. MEDLINE
8. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: (Suppl 1) 1–93. MEDLINE
9. Hummer M, Huber J: Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20: 189–97. MEDLINE
10. Nordstrom AL, Farde L: Plasma prolactin and central D2 receptor occupancy in antipsychotic drugs-treated patiens. J Clin Psychopharmacol 1998; 18: 305–10. MEDLINE
11. Straus SM, Bleumink GS, Dieleman JP et al.: Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164: 1293–7. MEDLINE
12. Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649–71. MEDLINE
13. Glassman AH, Bigger JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–84. MEDLINE
14. Haverkamp W, Haverkamp F, Breithardt G: Medikamentenbedingte QT-Verlängerung und Torsade de pointes. Dtsch Arztebl 2002; 99(28–29): A 1972–9. VOLLTEXT
15. Agelink MW, Majewski T, Wurthmann C et al.: Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001; 21: 8–13. MEDLINE
16. Baumann P, Hiemke C, Ulrich S et al., The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243–65. MEDLINE
17. Brodaty H, Ames D, Snowden J et al.: A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis in dementia. J Clin Psychiatry 2003; 64: 134–43. MEDLINE
18. Wooltorton E: Risperidone (Risperdal): increased rate of cerebrocascular events in dementia trials. CMAJ 2002; 167: 1269–70. MEDLINE
19. Wooltorton E: Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395. MEDLINE
20. Ballard C, Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006: CD003476. MEDLINE
21. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drugs treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43. MEDLINE
22. Liperoti R, Gambassi G, Lapane KL et al.: Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66: 1090–6. MEDLINE
23. Herrmann N, Mamdani M, Lanctot KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113–5. MEDLINE
24. Gill SS, Rochon PA, Herrmann N et al.: Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330. MEDLINE
25. Benkert O, Hippius H: Kompendium der psychiatrischen Pharmakotherapie. 5. Auflage. Heidelberg: Springer Verlag, Heidelberg; 205–6.
e1. Bagnall AM, Lewis RA, Leitner ML: Ziprasidon for schizophrenia and severe mental illness (Cochrane Review). In: The Cochrane Library, Issue 2, 2004; Chichester, UK: Wiley & Sons.
e2. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 553–64. MEDLINE
e3. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S: Olanzapine for schizophrenia (Cochrane Review) In: The Cochrane Library, Issue 2, 2004. Chichester, UK: Wiley & Sons.
e4. Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression and analysis. BMJ 200; 321: 1371–6. MEDLINE
e5. Hunter RH, Joy CB, Keennedy E, Gilbody SM, Song F: Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library , Issue 2, 2004; Chichester, UK: Wiley & Sons.
e6. Moto Neto JIS, Lima MS, Soares BGO: Amisulpride for schizophrenia. (Cochrane Review). In: The Cochrane Library, Issue 2, 2004; Chichester, UK: Wiley & Sons.
e7. Rummel C, Hamann J, Kissling W, Leucht S: New generation antipsychotics for first episode schizophrenia. (Cochrane Review). In: The Cochrane Library, Issue 2, 2004; Chichester, UK: Wiley & Sons.
e8. Srisurapanont M, Maneeton B, Maneeton N: Quetiapine for schizophrenia. (Cochrane Review). In: The Cochrane Library, 2004; Issue 2. Chichester, UK: Wiley & Sons.
e9. Leucht S, Barnes TRE, Kisslin W, Engel RR, Correl C, Kane JM: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomised, controlled trials. Am J Psychiatry 2003; 160: 1209–22. MEDLINE
e10. Möller HJ: Neue bzw. atypische Neuroleptika bei schizophrener Negativsymptomatik. Nervenarzt 2000; 71: 345–53. MEDLINE
e11. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O: Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997; 170: 18–22. MEDLINE
e12. Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466–74. MEDLINE
e13. Franz M, Lis S, Plüddemann, Gallhofer B: Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Brit J Psychiatry 1997; 170: 422–5. MEDLINE
e14. Hamilton SH, Revicki DA, Genduso LA, Beasley CM: Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998; 18: 42–9. MEDLINE
e15. Karow A, Naber D: Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3–10. MEDLINE
e16. Naber D: A self-rating to measure subjective effects of neuroleptic drugs: relation-ships to objektive psychopathology, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 (Suppl. 3): 133–8. MEDLINE
e17. Leucht S, Pitschel Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole, compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials, Schizophr Res 1999; 35: 51–68. MEDLINE
e18. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–9. MEDLINE
e19. Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8. MEDLINE
e20. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW: Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354–60. MEDLINE
e21. Valenstein M, Blow FC, Copeland LA et al.: Poor antipsychotics adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–64. MEDLINE
e22. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S: Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001; 155: 230–3. MEDLINE
e23. Chue P: The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective. Can J Psychiatry 2004; 49: 200–7. MEDLINE
e24. Koro CE, Fedder DO, L'Italien GJ et al.: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243–7. MEDLINE
e25. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–6. MEDLINE
e26. Gianfrancesco FD, Grogg AL, Mahmound RA, Wang RH, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on typ 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–30. MEDLINE
e27. Caro JJ, Ward A, Levinton C, Robinson K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002; 63: 1135–9. MEDLINE
e28. Gianfrancesco F, White R, Wang RH, Nasrallah HA: Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003; 23: 328–35. MEDLINE
e29. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164–70. MEDLINE
e30. Fuller MA, Shermock KM, Secic M, Grogg AL: Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003; 23: 1037–43. MEDLINE
e31. Leslie DL, Rosenheck RA: Insidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161: 1709–11. MEDLINE
e32. Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM: Weight gain and new onset diabetes associated with olanzapine and risperidone J Gen Intern Med 2004; 19: 1200–5. MEDLINE
e33. Ollendorf DA, Joyce AT, Rucker M: Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 2004; 6: 5. MEDLINE
e34. Ostbye T, Curtis LH, Masselink LE et al.: Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2005; 14: 407–15. MEDLINE
e35. Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G: Incidence of diabetes in a general practice population: a database Cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol 2005; 20: 33–7. MEDLINE
e36. Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W: Antipsychotic exposure and type 2 diabetes mamong patients with schizophrenia: a matched case-control study of California Medicaid claims. Phamacoepidemiol Drug Saf 2005; 14: 417–25. MEDLINE
e37. Moisan J, Gregoire JP, Gaudet M, Cooper D: Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a populations-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf 2005; 14: 427–36. MEDLINE
e38. Miller EA, Leslie DL, Rosenheck RA: Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005; 193: 387–95. MEDLINE
e39. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472–82. MEDLINE
e40. Breier A, Berg PH, Thakore JH et al.: Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005; 162: 1879–87. MEDLINE
e41. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu O: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 1837–47. MEDLINE
e42. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP: A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65: 696–701. MEDLINE
e43. Liebermann JA, Phillips M, Gu H et al.: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995–1003. MEDLINE
e44. Lindenmayer JP, Czobor P, Volavka J et al.: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–6. MEDLINE
e45. Koro CE, Fedder DO, L'Italien GJ et al.: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59: 1021–6. MEDLINE
e46. Lambert BL, Chang KY, Tafesse E, Carson W: Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol 2005; 25: 12–8. MEDLINE
e47. Atmaca M, Kologlu M, Tezcan E, Ustundag B: Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598–604. MEDLINE
e48. Sramek JJ, Cutler NR, Shiovitz T: The effect of antipsychotics on plasma lipids. J Clin Psychopharmacol 2003; 23: 679–80. MEDLINE
e49. McQuade RD, Stock E, Marcus R et al.: A comparison of weight change during treatment with olanzapine or aripiprazole: result from a randomized double-blind study. J Clin Psychiatry 2004; 65: (Suppl. 18): 47–56. MEDLINE
e50. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ: Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005; 162: 1535–8. MEDLINE
e51. Goodnick PJ, Jerry JM: Aripiprazole: profile on efficacy and safety. Expert Opin Phamacother 2002; 3: 1773–81. MEDLINE
e52. Coulouvrat C, Dondey-Nouvel L: Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14: 209–18. MEDLINE
e53. Melkersson K: Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005; 66: 761–7. MEDLINE
e54. Wudarsky M, Nicolson R, Hamburger SD et al.: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999; 9: 239–45. MEDLINE
e55. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57–71. MEDLINE
e56. Schlosser R, Grunder G, Anghelescu I et al.: Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002; 46: 33–40. MEDLINE
e57. Stubner S, Grohmann R, Engel R et al.: Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 (Suppl.1): S70–8. MEDLINE
e58. Thome J, Kopf D: Haematological abnormalities during treatment with atypical antipsychotics. Psychiatr Prax 2005; 32: 167–71. MEDLINE
e59. Viskin S, Justo D, Halkin A, Zeltser D: Long QT-syndrome caused by non-cardiac drugs. Prog Cardiovasc Dis 2003; 45: 415–27. MEDLINE
e60. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA: Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67: 774–6. MEDLINE
e61. Amann BL, Pogarell O, Mergl R et al.: EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olazapine, haloperidol and healthy subjects. Human Psychopharmacol 2003; 18: 641–6. MEDLINE
e62. Centorrino F, Price BH, Tuttle M et al.: EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002; 159: 109–15. MEDLINE
e63. Honer WG, Thornton AE, Chen EY et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472–82. MEDLINE
e64. Agelink MW, Kavuk I, Ak I: Clozapine with amisulprid for refractory schizophrenia. Am J Psychiatry 2004; 161: 924–5. MEDLINE
e65. Weber M, Wyne K: A cognitive behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006; 83: 95–101. MEDLINE
e66. Cordes J, Agelink MW: Neue Erkenntnisse zu Ursachen und Behandlung der Gewichtszunahme unter atypischen Antipsychotika. Symposium anlässlich des DGPPN-Kongress 2006; 22.–25.11.2006, Berlin.